Gut microbial metabolites in MASLD: Implications of mitochondrial dysfunction in the pathogenesis and treatment

• Published in: Hepatology communications Vol. 8; no. 7
• Main Authors: Zhang, Ruhan, Yan, Zhaobo, Zhong, Huan, Luo, Rong, Liu, Weiai, Xiong, Shulin, Liu, Qianyan, Liu, Mi
• Format: Journal Article
• Language: English
• Published: United States Lippincott Williams & Wilkins 01.07.2024
• Subjects: Animals; Anti-Bacterial Agents - therapeutic use; Fatty Liver - metabolism; Fatty Liver - microbiology; Fatty Liver - therapy; Fecal Microbiota Transplantation; Gastrointestinal Microbiome - physiology; Humans; Mitochondria - metabolism; Oxidative Stress; Prebiotics; Probiotics - therapeutic use; Review
• ISSN: 2471-254X; 2471-254X
• DOI: 10.1097/HC9.0000000000000484

With an increasing prevalence, metabolic dysfunction-associated steatotic liver disease (MASLD) has become a major global health problem. MASLD is well-known as a multifactorial disease. Mitochondrial dysfunction and alterations in the gut bacteria are 2 vital events in MASLD. Recent studies have highlighted the cross-talk between microbiota and mitochondria, and mitochondria are recognized as pivotal targets of the gut microbiota to modulate the host's physiological state. Mitochondrial dysfunction plays a vital role in MASLD and is associated with multiple pathological changes, including hepatocyte steatosis, oxidative stress, inflammation, and fibrosis. Metabolites are crucial mediators of the gut microbiota that influence extraintestinal organs. Additionally, regulation of the composition of gut bacteria may serve as a promising therapeutic strategy for MASLD. This study reviewed the potential roles of several common metabolites in MASLD, emphasizing their impact on mitochondrial function. Finally, we discuss the current treatments for MASLD, including probiotics, prebiotics, antibiotics, and fecal microbiota transplantation. These methods concentrate on restoring the gut microbiota to promote host health.